News for Organon & Co. (OGN-WI)

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Organon (OGN) strategically expands its portfolio by acquiring U.S. rights for the biosimilar TOFIDENCE from Biogen (BIIB). Analysts provide a favorable

Organon & Co. (OGN) reports revenues of $1.59 billion, aligning with last year's figures. Despite meeting revenue predictions, the full-year outlook dis

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authoriza

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Organon (OGN) concluded the recent trading session at $15.70, signifying a +0.51% move from its prior day's close.

Which of the largest U.S. companies rate highest on policies supporting working women, including paid parental leave, dependent care, flexible hours, and equal pay?

In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.

Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced results from an analysis of the Phase 3 ADORING 3 open-label,

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Organon & Co.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash f...

Organon & Co. (NYSE:OGN) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - CEOJuan...

The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The following slide deck was published by Organon & Co.

Organon (OGN) delivered earnings and revenue surprises of 4.65% and 1.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. ”œIn 2024 we achieved our third year of consta

Organon (OGN) concluded the recent trading session at $14.62, signifying a -1.81% move from its prior day's close.